Greenlane Holdings Inc

Aktienanalyse zu Greenlane Holdings Inc (GNLN)

$1.160

+0.020 (+1.75%)Zum Schluss

Loading chart…
Hoch
1.170
Eröffnung
1.130
Volumengewichteter Durchschnittskurs
1.15
Volumen
9.70K
Marktkap.
1.31M
Tief
1.110
Umsatz
11.12K
EV/EBITDA, TTM
0.00

Greenlane Holdings, Inc. provides a global platform for the development and distribution of smoking accessories, vape devices, and lifestyle products to producers, processors, specialty retailers, smoke shops, convenience stores, and retail consumers. The Company operates as a family of brands, third-party brand accelerator, and an omnichannel distribution platform. The Company offers its own diverse brand portfolio and its licensed Marley Natural and K.Haring branded products. It also offers a set of third-party products through its direct sales channels and its proprietary, owned and operated e-commerce platforms. Its Greenlane Brands include Groove, its smoke shop and ancillary product brand - Higher Standards, and its child-resistant packaging brand - Pollen Gear. It merchandises vaporizers, packaging, and other ancillary products in the United States, Canada, Europe, and Latin America. Its third-party brands include Storz and Bickel, Grenco Science, PAX, and Cookies.

gnln.com

KI-Analyse of Greenlane Holdings Inc (GNLN)

Verkaufen

Greenlane Holdings is not a good buy right now due to its current price of $1.14, a staggering year-to-date change of -90.98%, and an RSI of 9.42 indicating extreme oversold conditions. The company's financial health is concerning, with a net income loss of $24.83 million in Q2 2026 and a gross margin of only 54.99%, which is not sufficient to cover its operational costs. The primary risk is the high forward P/E ratio of 192.31, suggesting that the stock may be overvalued given its current financial performance.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Greenlane Holdings Inc (GNLN) beträgt 192.31, verglichen mit dem 5-Jahres-Durchschnitt von 46.55.

Erwartetes KGV

Überbewertet
5J-Durchschnitt P/E
46.55
Aktuelles P/E
192.31
Überbewertet
172.30
Unterbewertet
-79.21

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
2.95
Aktuelles EV/EBITDA
0.00
Überbewertet
17.20
Unterbewertet
-11.30

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
0.08
Aktuelles P/S
0.00
Überbewertet
0.20
Unterbewertet
-0.04

Event-Zeitleiste

2026-04-09 (ET)

11:41:00

Morgan Stanley's Bitcoin ETF Attracts $34M on First Day

07:40:00

Greenlane Authorizes $2M Share Repurchase Program

2026-04-02 (ET)

20:00:00

Greenlane Holdings Trading Halted, News Pending

2026-04-01 (ET)

08:20:00

Greenlane Announces 1-for-8 Reverse Stock Split

2026-03-03 (ET)

07:50:00

Company Holds Approximately 70.4M BERA Units and Deploys 50M Units

News

GNLN FAQ – beantwortet von Alphio AI

Greenlane Holdings, Inc. provides a global platform for the development and distribution of smoking accessories, vape devices, and lifestyle products to producers, processors, specialty retailers, smoke shops, convenience stores, and retail consumers. The Company operates as a family of brands, third-party brand accelerator, and an omnichannel distribution platform. The Company offers its own diverse brand portfolio and its licensed Marley Natural and K.Haring branded products. It also offers a set of third-party products through its direct sales channels and its proprietary, owned and operated e-commerce platforms. Its Greenlane Brands include Groove, its smoke shop and ancillary product brand - Higher Standards, and its child-resistant packaging brand - Pollen Gear. It merchandises vaporizers, packaging, and other ancillary products in the United States, Canada, Europe, and Latin America. Its third-party brands include Storz and Bickel, Grenco Science, PAX, and Cookies. It operates in the Consumer Non-Cyclicals sector (WHOLESALE-DURABLE GOODS, NEC industry).

Greenlane Holdings is not a good buy right now due to its current price of $1.14, a staggering year-to-date change of -90.98%, and an RSI of 9.42 indicating extreme oversold conditions. The company's financial health is concerning, with a net income loss of $24.83 million in Q2 2026 and a gross margin of only 54.99%, which is not sufficient to cover its operational costs. The primary risk is the high forward P/E ratio of 192.31, suggesting that the stock may be overvalued given its current financial performance.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Ähnliche Artikel

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln